Gilead Sciences, Inc. (BVMF:GILD34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 808.07B +8.3% |
| Revenue (ttm) | 155.12B +3.5% |
| Net Income | 48.08B +54.5% |
| EPS | 38.36 +55.4% |
| Shares Out | n/a |
| PE Ratio | 16.81 |
| Forward PE | 69.61 |
| Dividend | 5.78 (1.75%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 34 |
| Open | 332.80 |
| Previous Close | 337.84 |
| Day's Range | 330.05 - 332.80 |
| 52-Week Range | 293.72 - 396.35 |
| Beta | 0.33 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj... [Read more]
Financial Performance
In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.
Financial numbers in USD Financial StatementsNews
Gilead Sciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management highlighted a robust pipeline in virology, oncology, and inflammation, with strong HIV franchise growth and new long-acting therapies. Recent acquisitions and disciplined financial management support long-term growth, with no major patent expiries until 2036.
Merck, Gilead announce discontinuation of Phase 3 KEYNOTE-D46/EVOKE-03 study
Merck (MRK) and Gilead Sciences (GILD) announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead’s Trodelvy in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, ...
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the primary...
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
RAHWAY, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the...
Gilead announces launch of lenacapavir in South Africa
Gilead (GILD) applauds the leadership of the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. This marks an important ste...
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Access--Gilead applauds the leadership of the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV preventio...
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) today announced the successful complet...
GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases
Gilead announces results from Phase 3 study of Livdelzi
Gilead (GILD) Sciences announced results from a Phase 3 study in people with primary biliary cholangitis, showing that treatment with Livdelzi led to significantly more patients achieving normalizatio...
Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatmen...
Gilead Sciences Transcript: Bernstein 42nd Annual Strategic Decisions Conference
Poised for robust growth, the company expects up to 10 launches by 2027 and is expanding in HIV, oncology, and inflammation. Recent acquisitions strengthen the pipeline, while disciplined R&D and AI integration support top-tier margins and global health impact.
Gilead presents new Livdelzi data at EASL congress
Gilead (GILD) shared new results from a post hoc analysis showing that Livdelzi was associated with high and sustained rates of normalization of a key liver marker in people living…
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today shared new results from a post hoc analysis showing that Livdelzi® (seladelpar) was associated with high and sustained ...
US FDA approves Gilead's drug for deadly liver infection
The U.S. Food and Drug Administration said on Friday it approved Gilead Sciences' drug for a rare and deadly liver infection that previously had no approved treatment options.
FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Hepcludex® (bulevirtide...
Gilead receives positive CHMP opinion for Trodelvy in TNBC
Gilead (GILD) Sciences announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending the marketing authorization of Tr...
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ado...
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that together with Kite, a Gilead company, it will present more than 25 abstracts, inc...
Gilead completes acquisition of Tubulis for $3.15B upfront
Gilead (GILD) Sciences announced the completion of its previously announced acquisition of Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibo...
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Tubulis GmbH, a private Germany-based, c...
Gilead renews five-year collaboration with World Health Organization
Gilead (GILD) Sciences announced a renewed five-year collaboration with the World Health Organization, committing funding, strategic support and product donations to accelerate progress toward elimina...
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a renewed five-year collaboration with the World Health Organization (WHO), committing funding, strategic sup...
RBC Capital remains ‘conservative’ on Gilead’s Trodelvy and Yeztugo
RBC Capital keeps a Sector Perform rating and $122 price target on Gilead (GILD) after hosting the RBC healthcare conference with a presentation by the company CMO. There was high…
Gilead upgraded to Buy at Maxim on approaching growth drivers, valuation
Maxim analyst Michael Okunewitch upgraded Gilead (GILD) to Buy from Hold with a $165 price target The company’s growth in the base business is expected to reach 5%-6%, exceeding the…
Gilead upgraded to Buy from Hold at Maxim
Maxim analyst Michael Okunewitch upgraded Gilead (GILD) to Buy from Hold with a $165 price target